DRTG(600329)2020-04-29 16:00Financial Performance - Net profit attributable to shareholders decreased by 10.59% to CNY 169,889,787.25 year-on-year[4] - Operating revenue decreased by 5.56% to CNY 1,655,960,806.79 compared to the same period last year[4] - Basic earnings per share decreased by 10.53% to CNY 0.221 per share[4] - The company reported a decrease in net profit after deducting non-recurring gains and losses by 8.27% to CNY 157,338,706.11[4] - The company reported a significant increase in credit impairment losses, rising by 931% year-on-year to RMB -3,973,420.16[10] - Total profit for Q1 2020 was ¥196,635,669.69, down from ¥217,635,842.43 in Q1 2019, a decrease of 9.56%[19] - Total operating revenue for Q1 2020 was ¥1,655,960,806.79, a decrease of 5.57% compared to ¥1,753,428,846.52 in Q1 2019[18] Assets and Liabilities - Total assets increased by 2.70% to CNY 8,054,874,609.75 compared to the end of the previous year[4] - The total number of shareholders reached 33,639 at the end of the reporting period[7] - The total liabilities increased slightly from RMB 2,157,206,952.90 to RMB 2,198,840,077.38, indicating stable financial leverage[14] - Current assets totaled ¥4,874,396,862.26, up from ¥4,654,640,364.36, indicating an increase of about 4.72%[16] - Non-current assets amounted to ¥2,652,052,110.85, slightly rising from ¥2,638,273,033.18, representing a growth of approximately 0.52%[16] - Total liabilities reached ¥1,982,468,159.10, compared to ¥1,937,633,454.71, marking an increase of around 2.31%[17] Cash Flow - Net cash flow from operating activities increased by 20.07% to CNY 138,077,046.98 year-on-year[4] - Cash inflow from operating activities totaled CNY 1,220,431,063.67 in Q1 2020, compared to CNY 1,449,080,246.02 in Q1 2019, representing a decrease of approximately 15.8%[22] - Cash inflow from sales of goods and services was CNY 1,194,225,469.09 in Q1 2020, compared to CNY 1,436,734,452.35 in Q1 2019, a decline of about 17.0%[22] - Cash and cash equivalents at the end of Q1 2020 amounted to CNY 1,600,610,380.18, compared to CNY 1,465,899,415.39 at the end of Q1 2019, reflecting an increase of about 9.2%[24] - Net cash flow from investment activities was negative CNY 11,539,511.36 in Q1 2020, an improvement from negative CNY 51,911,517.93 in Q1 2019[23] Shareholder Information - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 42.847% of the shares[7] - Shareholders' equity totaled ¥5,543,980,814.01, up from ¥5,355,279,942.83, reflecting a growth of approximately 3.52%[17] Operational Efficiency - Inventory decreased from RMB 1,594,557,577.10 to RMB 1,373,564,858.60, indicating improved inventory management[13] - Sales expenses for Q1 2020 were ¥433,018,634.55, a reduction of 14.12% from ¥504,583,700.78 in Q1 2019[18] - Tax expenses for Q1 2020 were ¥22,038,531.65, down from ¥26,052,381.48 in Q1 2019, reflecting a decrease of 15.43%[19] Other Financial Metrics - The weighted average return on net assets decreased by 0.68 percentage points to 3.10%[4] - Other income rose significantly by 525% year-on-year, from RMB 1,920,259.48 to RMB 11,999,677.53, primarily due to an increase in government subsidies[10] - Financial expenses increased by 188% year-on-year, from RMB -1,693,024.71 to RMB -4,882,603.42, mainly due to a decrease in interest expenses[10] - The company has not disclosed any new product developments or market expansion strategies in this report[3] - The company has not indicated any significant changes in its future profit outlook or major commitments that remain unfulfilled[12]